-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Lagociclovir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/92562-88-4.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 92562-88-4 |
| Description | Lagociclovir is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV. |
Product Information
| Synonyms | MIV-210; MIV 210; MIV210; 3'-FddG; Fddguo; Lagociclovir. |
| IUPAC Name | 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one |
| Molecular Weight | 269.23 |
| Molecular Formula | C10H12FN5O3 |
| Canonical SMILES | C1C(C(OC1N2C=NC3=C2NC(=NC3=O)N)CO)F |
| InChI | InChI=1S/C10H12FN5O3/c11-4-1-6(19-5(4)2-17)16-3-13-7-8(16)14-10(12)15-9(7)18/h3-6,17H,1-2H2,(H3,12,14,15,18)/t4-,5+,6+/m0/s1 |
| InChIKey | RTJUXLYUUDBAJN-KVQBGUIXSA-N |
| Boiling Point | 633.5±65.0 °C at 760 mmHg |
| Flash Point | 336.9±34.3 °C |
| Purity | >98% |
| Density | 2.0±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Application | Antiviral Agents |
| Storage | Store at -20°C |
| Complexity | 420 |
| Exact Mass | 269.09241742 |
| Index Of Refraction | 1.834 |
| In Vitro | Oral administration of MIV-210 at 20 or 60 mg/kg of body weight/day induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following week period. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA. |
| PSA | 119.05000 |
| Target | HBV |
| Vapor Pressure | 0.0±2.0 mmHg at 25°C |
| XLogP3-AA | -0.9 |
